ConvaTec, the UK-based medical products company, is shaping up to be a second-half story in 2026, according to analysts at Bernstein. The firm expects the company's adjusted operating profit margin (EBITA margin) to climb to 25.1% in the second half of the year, up from 20.9% in the first half. That improvement hinges on tighter cost control and a shift toward higher-margin products, particularly in its Infusion Devices division.
What's Driving the Margin Forecast?
Bernstein's analysis points to two main levers. First, the firm believes ConvaTec can keep its operating expenses (OPEX) flat from the first half to the second half. If sales rise later in the year—as the company typically sees seasonal strength—more of each additional dollar of revenue would flow straight to profit. Second, the product mix is expected to improve. Infusion Devices, a unit that carries higher margins than some of ConvaTec's other product lines, is forecast to make up a larger share of sales in the second half.
Bernstein also notes that recent restructuring savings should become more visible in the second half. The logic is that restructuring initiatives often take time to implement, with costs incurred early in the year and benefits materializing later. That pattern is common across many companies undergoing operational overhauls, as seen in other sectors like retail where Bernstein has warned about fading margin gains.
Why the Timing Matters for Investors
For shareholders, the key takeaway is that ConvaTec's 2026 profit story depends heavily on the timing of that second-half pickup. When a company plans to hold costs steady and rely on stronger sales later in the year, even small delays in revenue can have an outsized impact on profits. If Infusion Devices momentum or restructuring benefits arrive later than expected, the revenue shortfall could translate into a bigger-than-expected EBITA miss because expenses don't fall in tandem.
Bernstein is sticking with a 2.75 pounds sterling price target and describes the current valuation—roughly 13 times forward earnings—as an "opportunity." But that call comes with a caveat: the stock's narrative is sensitive to each update on the building blocks for the second half. Investors will be watching for evidence in early 2026 that OPEX remains flat, Infusion Devices mix is improving, and restructuring savings are showing up in the numbers.
Broader Context: Medical Products and Margin Trends
ConvaTec operates in the medical supplies and devices space, a sector where margins can vary widely depending on product mix and manufacturing efficiency. The company's focus on wound care, ostomy care, and infusion devices means it competes with both large diversified healthcare firms and specialized players. Margin expansion is a common goal for such companies, but achieving it often requires a combination of cost discipline and revenue growth.
Bernstein's analysis fits into a broader pattern where analysts are scrutinizing companies' ability to improve profitability without relying on aggressive cost-cutting that could hurt long-term growth. In ConvaTec's case, the emphasis on Infusion Devices—a higher-margin segment—suggests the company is trying to shift its revenue mix toward more profitable products, a strategy that can pay off if executed well.
What to Watch Next
For everyday investors, the near-term debate around ConvaTec is less about the full-year math and more about the evidence that the building blocks for the second half are in place. Key milestones will include quarterly updates on OPEX trends, sales performance in Infusion Devices, and any signs that restructuring savings are flowing through to the bottom line.
If those signals emerge early in 2026, the stock's current valuation could indeed look attractive. But if delays appear, the stock could become more volatile with each earnings report. As with any investment that depends on timing, patience and close attention to operational details will be important.
For context on how other companies are navigating similar margin dynamics, see our coverage of AI revenue trends and Bernstein's recent analysis of GSK.
